Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.58 |
| ▸ | ESRRG | P62508 | 8/20 | 0.50 |
| ▸ | ESRRB | O95718 | 5/20 | 0.50 |
| ▸ | ESR1 | P03372 | 4/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4652120 | 0.98 | KCNH2 (0.57) | KCNH2HRH3ESRRGESRRBESR1 | |
| SCHEMBL25453173 | 0.87 | HRH3 (0.55) | KCNH2HRH3ESRRGESRRBESR1 | |
| SCHEMBL16304063 | 0.86 | KCNH2 (0.54) | KCNH2HRH3ESRRGESRRBESR1 | |
| SCHEMBL4653289 | 0.83 | HRH3 (0.51) | KCNH2HRH3ESRRGESRRBESR1 | |
| SCHEMBL23384133 | 0.83 | HRH3 (0.51) | KCNH2HRH3ESRRGESRRBESR1 | |
| Iodide SCHEMBL4653287 | 0.82 | HRH3 (0.50) | KCNH2HRH3ESRRGESRRBESR1 | |
| SCHEMBL10057672 | 0.82 | KMO (0.61) | KCNH2HRH3ESRRGESRRBESR1 | |
| SCHEMBL1305458 | 0.81 | HDAC3 (0.55) | ESRRGUSP2ALDH1A1MLYCD | |
| SCHEMBL15379923 | 0.81 | NAMPT (0.56) | KCNH2HRH3CCR1 | |
| SCHEMBL18403655 | 0.81 | KCNH2 (0.48) | KCNH2HRH3ESRRGESRRBESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-20220041559-A1 | BENZO-AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
| WO-2021202600-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-10-07 | — | — | WO | disclosed |
| US-8877927-B2 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl proteinase inhibitors | GRUNENTHAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| EP-2044075-B1 | FURO [3, 2-B] PYRROL DERIVATIVES | AMURA THERAPEUTICS LTD (GB) | 2013-01-02 | — | — | EP | disclosed |
| EP-2046796-B1 | TETRAHYDROFURO [3, 2 -B]PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-10-24 | — | — | EP | disclosed |
| EP-2046795-B1 | FURO[3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-10-17 | — | — | EP | disclosed |
| EP-2046797-B1 | FURO [3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-05-23 | — | — | EP | disclosed |
| EP-2046798-B1 | FURO [3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-05-16 | — | — | EP | disclosed |
| US-8053437-B2 | Furo[3. 2-B] pyrrol derivatives | AMURA THERAPEUTICS LIMITED (GB) | 2011-11-08 | — | — | US | disclosed |
| WO-2008007127-A1 | FURO [3,2-B] PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007114-A1 | TETRAHYDROFURO [3, 2 -B] PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007109-A1 | FURO[3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007103-A1 | FURO [3, 2-B] PYRROL DERIVATIVES | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007130-A1 | FURO [3,2-B] PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007112-A1 | TETRAHYDROFURO [3, 2-B] PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
| CN-1636980-A | Dipeptide nitrile cathepsin K inhibitors | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | disclosed |
| CN-1183122-C | Dipeptide nitrile cathepsin K inhibitors | ��˹��ŵ�� | 2005-01-05 | — | — | CN | disclosed |
| CN-1398260-A | Dipeptide nitrile cathepsin K inhibitors | NOVARTIS AG (CH) | 2003-02-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041559-A1 | BENZO-AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | PDXK, MAP4K2, PLK2 | KCNH2 3042/4885HRH3 4015/4885ESRRG 2081/4885 |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | KCNH2 3229/4885HRH3 13/4885ESRRG 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.